Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; a… Read more
Klaria Pharma Holding AB - Asset Resilience Ratio
Klaria Pharma Holding AB (KLAR) has an Asset Resilience Ratio of 5.36% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Klaria Pharma Holding AB's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Klaria Pharma Holding AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr2.54 Million | 5.36% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr2.54 Million | 5.36% |
Asset Resilience Insights
- Limited Liquidity: Klaria Pharma Holding AB maintains only 5.36% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Klaria Pharma Holding AB Industry Peers by Asset Resilience Ratio
Compare Klaria Pharma Holding AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Klaria Pharma Holding AB (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Klaria Pharma Holding AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.04% | Skr598.00K | Skr57.27 Million | -0.67pp |
| 2023-12-31 | 1.71% | Skr1.25 Million | Skr72.95 Million | -12.23pp |
| 2022-12-31 | 13.94% | Skr16.76 Million | Skr120.27 Million | -7.61pp |
| 2021-12-31 | 21.55% | Skr25.49 Million | Skr118.31 Million | -2.06pp |
| 2020-12-31 | 23.60% | Skr31.25 Million | Skr132.41 Million | +20.74pp |
| 2019-12-31 | 2.87% | Skr2.92 Million | Skr101.73 Million | -4.62pp |
| 2018-12-31 | 7.49% | Skr7.96 Million | Skr106.25 Million | -3.48pp |
| 2017-12-31 | 10.97% | Skr17.10 Million | Skr155.87 Million | -8.22pp |
| 2016-12-31 | 19.19% | Skr31.10 Million | Skr162.03 Million | -- |